Across the US and EU, life sciences companies are pushing diagnostics, antibody testing, vaccines and other efforts forward to flatten the Coronavirus (COVID-19) curve. Our multidisciplinary cross-border life sciences team will examine the current global market and industry issues and offer perspectives on what is on the horizon for the life sciences sector and its stakeholders. The program will address:

• The current state of diagnostics, antibody testing and vaccine development, and accelerated pathways for certification, approval, reimbursement and market access
• Considerations for deal structures, key diligence concerns and foreign investment controls during this unique time
• Emerging digital solutions, including the development and deployment of digital therapeutics, diagnostics and other tools
• Outlook for life sciences M&A and transformations of industry partnerships during and after COVID-19

We want to ensure we address the issues of most importance to our participants, and we encourage you to submit your questions for the panel in advance during registration.

DURING THIS WEBINAR, WE WILL COVER:

• OPENING REMARKS
• REGULATORY AND SCIENTIFIC OVERVIEW
  • Overview of test and vaccine development and accelerated pathways for certification, approval, and reimbursement and market access
• TRANSACTIONAL
  • Deal structures: joint ventures, control and minority acquisitions as well restructuring and divestitures
  • Key diligence concerns: regulatory and IP
  • Foreign investment control
• DIGITAL SOLUTIONS
  • Development and deployment of digital tools, including contact tracing/apps
• CLOSING REMARKS – LOOKING TOWARD THE FUTURE
  • M&A outlook and transformation in partnerships